WHIM Publications

The publications listed below are offered for informational purposes only and do not represent all publications to which X4 Pharmaceuticals or its collaboration partners have contributed or may contribute or that relate to X4 Pharmaceuticals’ product candidates. These publications are made available by third parties, and the content of any linked third-party site is the responsibility of the third party, not X4 Pharmaceuticals, and X4 Pharmaceuticals disclaims liability for the linked content.

WHIM

N Engl J Med. 2019 Jan 10;380(2):163-170. doi: 10.1056/NEJMoa1808575.

Plerixafor for the Treatment of WHIM Syndrome.

McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM.

J Allergy Clin Immunol Pract. 2019 May – Jun;7(5):1568-1577. doi: 10.1016/j.jaip.2019.01.045. Epub 2019 Feb 2.

Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies.

Dotta L¹, Notarangelo LD², Moratto D³, Kumar R³, Porta F², Soresina A⁴, Lougaris V⁵, Plebani A⁵, Smith CIE⁶, Norlin AC⁷, Gòmez Raccio AC⁸, Bubanska E⁹, Bertolini P¹⁰, Amendola G¹¹, Visentini M¹², Fiorilli M¹², Venuti A¹³, Badolato R⁵.

Blood. 2017 Dec 7;130(23):2491-2498. doi: 10.1182/blood-2017-02-708552. Epub 2017 Oct 24.

How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Badolato R^1,2, Donadieu J³; WHIM Research Group.

Blood. 2011 Nov 3;118(18):4957-62. doi: 10.1182/blood-2011-07-368084. Epub 2011 Sep 2.

The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

McDermott DH¹, Liu Q, Ulrick J, Kwatemaa N, Anaya-O’Brien S, Penzak SR, Filho JO, Priel DA, Kelly C, Garofalo M, Littel P, Marquesen MM, Hilligoss D, Decastro R, Fleisher TA, Kuhns DB, Malech HL, Murphy PM.

Clin Immunol. 2010 Jun;135(3):412-21. doi: 10.1016/j.clim.2010.02.006. Epub 2010 Mar 11.

Oligoclonality, impaired class switch and B-cell memory responses in WHIM syndrome.

Mc Guire PJ¹, Cunningham-Rundles C, Ochs H, Diaz GA.

Blood. 2004 Jul 15;104(2):444-52. Epub 2004 Mar 16.

Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome.

Gulino AV¹, Moratto D, Sozzani S, Cavadini P, Otero K, Tassone L, Imberti L, Pirovano S, Notarangelo LD, Soresina R, Mazzolari E, Nelson DL, Notarangelo LD, Badolato R.

Nat Genet. 2003 May;34(1):70-4.

Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease.

Hernandez PA¹, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, Klotman ME, Diaz GA.

Primary Immunodeficiencies

Clin Rev Allergy Immunol. 2014 Apr;46(2):145-53. doi: 10.1007/s12016-013-8380-0.

New genetic discoveries and primary immune deficiencies.

Hernandez-Trujillo V¹.

J Clin Immunol. 2007 Sep;27(5):497-502. Epub 2007 Jun 19.

Population prevalence of diagnosed primary immunodeficiency diseases in the United States.

Boyle JM¹, Buckley RH.

J Allergy Clin Immunol. 2012 Nov;130(5):1030-48. doi: 10.1016/j.jaci.2012.07.049. Epub 2012 Oct 1.

Warts and all: human papillomavirus in primary immunodeficiencies.

Leiding JW¹, Holland SM.

Blood. 2010 Oct 14;116(15):2793-802. doi: 10.1182/blood-2010-01-265942. Epub 2010 Jul 8.

Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis.

McDermott DH¹, De Ravin SS, Jun HS, Liu Q, Priel DA, Noel P, Takemoto CM, Ojode T, Paul SM, Dunsmore KP, Hilligoss D, Marquesen M, Ulrick J, Kuhns DB, Chou JY, Malech HL, Murphy PM.